Inclusion Criteria:

1. Women aged from 18 to 65 years;

2. Histologically or cytologically proven invasive unilateral breast cancer (regardless
of the type);

3. Initial clinical condition compatible with complete initial resection;

4. No residual macro or microscopic tumor after surgical excision;

5. Patient presenting one of the following criteria (reviewed before randomization by
referent pathologist):

Triple Negative(ER-PR-Her-2-) Hormone receptor negativity is defined as ER<10%,
PR<10% (IHC), HER2 negativity is defined as IHC 0-1+, or [IHC 2+ and FISH or CISH
negative].

6. No clinically or radiologically detectable metastases (M0);

7. No peripheral neuropathy > 1;

8. WHO Performance status (ECOG) of 0 or 1;

9. Adequate hematological function (neutrophil count ³ 2x109/l, platelet count ³ 100x
109/l, Hemoglobin > 9 g/dl);

10. Adequate hepatic function: ASAT and ALAT £ 1.5 ULN alkaline phosphatases £ 2.5
ULN,total bilirubin £ 1,5 ULN;

11. Adequate renal function: serum creatinine £ 1.5 ULN;

12. Patients accepting contraception intake during the overall length of treatment if of
childbearing potential;

13. Adequate cardiac function, LEVF value > 50% by Muga scan or echocardiography;

14. Signed written informed consent.

Exclusion Criteria:

1. Bilateral breast cancer or patient with controlateral DCIS;

2. Any metastatic impairment, including homolateral sub-clavicular node
involvement,regardless of its type;

3. Any tumor ³ T4a (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast
cancer);

4. Luminal A, Luminal B and Her-2 overexpression

5. Any clinically or radiologically suspect and non-explored damage to the controlateral
breast;

6. Previous cancer (excepted cutaneous baso-cellular epithelioma or uterine peripheral
epithelioma) in the preceding 5 years, including invasive controlateral breast
cancer;

7. Patients already included in another therapeutic trial involving an experimental
drug;

8. Patients with other concurrent severe and/or uncontrolled medical disease or
infection which could compromise participation in the study;

9. LEVF < 50% (MUGA scan or echocardiography);

10. Clinically significant cardiovascular disease (e.g. unstable angina, congestive heart
failure, uncontrolled hypertension (>150/90), myocardial infarction or cerebral
vascular accidents) within 6 months prior to randomization;

11. Known prior severe hypersensitivity reactions to agents in this study

12. Women of childbearing potential who are unwilling or unable to use an acceptable
method to avoid pregnancy for the entire study period and up to 8 weeks after
treatment completion;

14) Women who are pregnant or breastfeeding. Adequate birth control measures should be
taken during study treatment phase; 15) Women with a positive pregnancy test en enrollment
or prior to study drug administration; 16) Patients with any psychological, familial,
sociological or geographical condition potentially hampering compliance with the study
protocol and follow-up schedule; those conditions should be discussed with the patient
before registration in the trial; 17) Individual deprived of liberty or placed under the
authority of a tutor.